Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415756 | 0.84 | CES2 (0.41) | CES2CES1IDO1TDO2HDAC4 | |
| SCHEMBL31067420 | 0.84 | IDO1 (0.42) | CES2CES1IDO1TDO2BRD4 | |
| SCHEMBL17064312 | 0.84 | IDO1 (0.42) | CES2CES1IDO1TDO2BRD4 | |
| SCHEMBL14528193 | 0.82 | GAA (0.53) | CES2CES1IDO1TDO2HDAC4 | |
| SCHEMBL30986736 | 0.82 | HDAC4 (0.44) | CES2CES1IDO1TDO2HDAC4 | |
| SCHEMBL27589337 | 0.82 | IDO1 (0.40) | CES2CES1IDO1TDO2HDAC4 | |
| SCHEMBL30986701 | 0.82 | IDO1 (0.50) | CES2CES1IDO1TDO2BRD4 | |
| SCHEMBL477718 | 0.82 | IDO1 (0.50) | CES2CES1IDO1TDO2BRD4 | |
| SCHEMBL30910884 | 0.82 | IDO1 (0.50) | CES2CES1IDO1TDO2BRD4 | |
| SCHEMBL3858520 | 0.82 | IDO1 (0.50) | CES2CES1IDO1TDO2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440690-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8404712-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-26 | — | — | US | disclosed |
| EP-2313404-B1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2012-03-28 | — | — | EP | disclosed |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-20110319444-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-29 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| CN-102112474-A | Quinuclidine carbonate derivatives and medicinal composition thereof | CHIESI FARMA SPA | 2011-06-29 | — | — | CN | disclosed |
| EP-2313404-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010015324-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | CES2 2730/4885CES1 1576/4885IDO1 1692/4885 |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | CES2 2730/4885CES1 1576/4885IDO1 1692/4885 |
| US-20110319444-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | CES2 2730/4885CES1 1576/4885IDO1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.